← All candidates
One insider buy in the last year — $125.0K in all.
46 filings on record.
IVVDInvivyd, Inc.
NasdaqGM · Healthcare · $255.03M
$0.8918
+13.46% · Sep 14
One insider buy in the last year — $125.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 20 sells◆ 11 8-K
▸ hover a marker for the filing · drag to zoom · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$255.03M
Float
207.8M
71% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
4.4
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Mclaughlin Kevin F
Bought $125.0K on Nov 19 — 50,000 sh @ $2.50, held direct, 100% of their stake.
0 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
41 more transactions on Pro →Context
Wall St
$10.00 avg target
+1021.3% vs today · 3 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 3 quarters beat
Q1 '26−$0.13 act−$0.05
Q3 '25−$0.06 act+$0.04
Q2 '25−$0.12 act−$0.13
Coverage
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311Insider Monkey · 06-19Invivyd doses first participants in Phase 3 COVID-19 trialProactive · 06-09Invivyd Doses First Participants in Phase 3 Trial of COVID-19 Antibody VYD2311MT Newswires · 06-09This Invivyd Insider Increased Their Holding In The Last YearSimply Wall St. · 06-06
The file stays open
46 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice